Research graph
References from Farletuzumab ecteribulin, a folate receptor alpha (FRα) antibody-drug conjugate, in select advanced cancers: An open-label, multicenter, phase 1/2 dose-finding study. Local targets link to admitted publications; unresolved targets remain external evidence.
Unresolved reference
External reference
Unresolved reference
External reference
Folate receptor alpha in advanced epithelial ovarian cancer: diagnostic role and therapeutic implications of a clinically validated biomarker
10.3390/ijms26115222 · 2025 · External reference
Folate receptor alpha—a novel approach to cancer therapy
10.3390/ijms25021046 · 2024 · External reference
Exploring the therapeutic use and outcome of antibody-drug conjugates in ovarian cancer treatment
10.1038/s41388-025-03448-3 · 2025 · External reference
Advances in antibody-drug conjugates for endometrial cancer
10.1158/1535-7163.mct-24-0763 · 2025 · External reference
Unresolved reference
2025 · External reference
Unresolved reference
External reference
Mirvetuximab soravtansine in FRα-positive, platinum-resistant ovarian cancer
10.1056/nejmoa2309169 · 2023 · External reference
First-in-human phase 1 study of MORAb-202, an antibody-drug conjugate comprising farletuzumab linked to eribulin mesylate, in patients with folate receptor-α-positive advanced solid tumors
10.1158/1078-0432.ccr-20-4740 · 2021 · External reference
Folate receptor alpha for cancer therapy: an antibody and antibody-drug conjugate target coming of age
10.1080/19420862.2025.2470309 · 2025 · External reference
Results from the first-in-human phase I study of LY4170156, an antibody drug conjugate (ADC) targeting folate receptor alpha in recurrent platinum resistant high-grade serous ovarian cancer (HGSOC) [abstract]
10.1016/j.annonc.2025.08.1707 · 2025 · External reference
Safety and efficacy of BAT8006, a folate receptor α (FRα) antibody drug conjugate, in patients with platinum-resistant ovarian cancer: update on the dose optimization/expansion cohort of BAT-8006-001-CR trial [abstract]
2025 · External reference
First-in-human study of AZD5335, a folate receptor α (FRα)-targeted antibody-drug conjugate, in patients with platinum-resistant recurrent ovarian cancer [abstract]
10.1016/j.annonc.2025.08.1705 · 2025 · External reference
A phase I/II study of rinatabart sesutecan (Rina-S) in patients with advanced ovarian or endometrial cancer [abstract]
2024 · External reference
Safety and efficacy of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer
10.1016/j.ygyno.2023.01.020 · 2023 · External reference
Antibody-drug conjugate combinations in cancer treatment: clinical efficacy and clinical study perspectives
2025 · External reference
Safety and efficacy of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with pembrolizumab in patients with platinum-resistant ovarian cancer
10.1016/j.ygyno.2025.06.016 · 2025 · External reference
Rinatabart sesutecan (Rina-S) for patients with advanced endometrial cancer: first disclosure from dose expansion cohort B2 of the GTC1184–01 study [abstract]
2025 · External reference
MORAb-202, an antibody-drug conjugate utilizing humanized anti-human FRα farletuzumab and the microtubule-targeting agent eribulin, has potent antitumor activity
10.1158/1535-7163.mct-17-1215 · 2018 · External reference
Unresolved reference
2022 · External reference
Unresolved reference
External reference
Unresolved reference
External reference
Antibody-drug conjugate MORAb-202 exhibits long-lasting antitumor efficacy in TNBC PDx models
10.1111/cas.14898 · 2021 · External reference
Preclinical and early clinical development of MORAb-202, a folate receptor alpha-targeted antibody-drug conjugate, which utilizes Halaven as payload at first time
2021 · External reference
10.1016/s0959-8049(22)01032-2
10.1016/s0959-8049(22)01032-2 · External reference
Antitumor effect of farletuzumab ecteribulin in molecular subtypes of endometrial cancer patient-derived xenograft models
10.1158/1535-7163.mct-25-0035 · 2025 · External reference
Clinical trial of safety and antitumor activity of farletuzumab ecteribulin in patients with platinum-resistant ovarian cancer: phase I expansion results
2025 · External reference
Shortening the timeline of pediatric phase I trials: the rolling six design
10.1200/jco.2007.12.7712 · 2008 · External reference
Pharmacokinetic and exposure-response modeling support body surface area-based dosing of farletuzumab ecteribulin in Japanese patients with solid tumors
10.1002/jcph.6187 · 2025 · External reference
Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline
10.1200/jco.2017.77.6385 · 2018 · External reference
Management of interstitial lung disease associated with connective tissue disease
2016 · External reference
A confidence interval for the median survival time
10.2307/2530286 · 1982 · External reference
Treatment-related adverse events of antibody-drug conjugates in clinical trials: a systematic review and meta-analysis
10.1002/cncr.34507 · 2023 · External reference
10.1016/s0090-8258(21)00717-4
10.1016/s0090-8258(21)00717-4 · 2021 · External reference
Eribulin-induced interstitial pneumonia: a case series and retrospective cohort study
10.2169/internalmedicine.2779-19 · 2020 · External reference
Unresolved reference
2025 · External reference
